A28 - RFQ 15DDHQ25Q0000093-1.pdf

15DDHQ25Q00000093 Page 1 of 58

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES

NOTE: OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24 AND 30.

1. REQUISITION NUMBER

D-25-DO-0003

PAGE 1 OF

5. SOLICITATION NUMBER

15DDHQ25Q00000093

2. CONTRACT NUMBER 3. AWARD/EFFECTIVE

DATE

4. ORDER NUMBER 6. SOLICITATION ISSUE

DATE

6/4/2025

7. FOR SOLICITATION

INFORMATION CALL:

a. NAME b. TELEPHONE NUMBER (No collect calls) 8. OFFER DUE DATE / LOCAL

TIME

06/16/2025 04:00 ET

CODE 15DDHQ

DEA

Attn: Office of Acquisition (FA)

8701 Morrissette Drive

Springfield, VA 22152-1080

9. ISSUED BY X UNRESTRICTED OR SET ASIDE: % FOR

SMALL BUSINESS

HUBZONE SMALL

BUSINESS

SERVICE-DISABLED

VETERAN-OWNED

SMALL BUSINESS

(SDVOSB)

WOMEN-OWNED SMALL

BUSINESS (WOSB)

ECONOMICALLY DISADVANTAGED

WOMEN-OWNED SMALL BUSINESS

(EDWOSB)

8(A)

NORTH AMERICAN

INDUSTRY CLASSIFICATION

STANDARD (NAICS): 541519

SIZE STANDARD: $34M

10. THE ACQUISITION IS

SEE SCHEDULE

11. DELIVERY FOR FREE ON BOARD

(FOB) DESTINATION UNLESS

BLOCK IS MARKED

NET 30

12. DISCOUNT TERMS

13a. THIS CONTRACT IS A

RATED ORDER UNDER THE

DEFENSE PRIORITIES AND

ALLOCATIONS SYSTEM -

DPAS (15 CFR 700)

13b. RATING

X REQUEST

FOR QUOTE

(RFQ)

INVITATION

FOR BID

(IFB)

REQUEST

FOR

PROPOSAL

(RFP)

14. METHOD OF SOLICITATION

CODE15. DELIVER TO

SEE SCHEDULE

CODE 15DDHQ16. ADMINISTERED BY

DEA Headquarters 600/700 Army-Navy Dr, Lincoln Pl Arlington, VA 22202-4207

Kathrine Leach Kathrine.r.leach@dea.gov

FACILITY

CODE

CODE

TELEPHONE NUMBER

17a. CONTRACTOR/

OFFEROR

CODE18a. PAYMENT WILL BE MADE BY

17b. CHECK IF REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN

OFFER SEE ADDENDUM

18b. SUBMIT INVOICES TO ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK

BELOW IS CHECKED

19.

ITEM NUMBER

20.

SCHEDULE OF SUPPLIES/SERVICES

21.

QUANTITY

22.

UNIT

23.

UNIT PRICE

24.

AMOUNT

This is a RFQ for RX Prescription Data IAW SOW and schedule of services. This is a Firm-Fixed Price requirement. Offerors shall quote IAW the Instructions to offerors provided in this RFQ.

Questions may be directed to Kathrine.r.leach@dea.gov

See Continuation Sheet(s) (Use Reverse and/or Attach Additional Sheets as Necessary)

25. ACCOUNTING AND APPROPRIATION DATA 26. TOTAL AWARD AMOUNT (For Government Use Only)

X 27a. SOLICITATION INCORPORATES BY REFERENCE (FEDERAL ACQUISITION REGULATION) FAR 52.212-1, 52.212-4. FAR 52.212-3

AND 52.212-5 ARE ATTACHED. ADDENDA

ARE ARE NOT ATTACHED

27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR 52.212-4. FAR 52.212-5 IS ATTACHED. ADDENDA ARE ARE NOT ATTACHED

28. CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN ____ COPIES TO

ISSUING OFFICE. CONTRACTOR AGREES TO FURNISH AND DELIVER ALL ITEMS SET FORTH

OR OTHERWISE IDENTIFIED ABOVE AND ON ANY ADDITIONAL SHEETS SUBJECT TO THE

TERMS AND CONDITIONS SPECIFIED.

29. AWARD OF CONTRACT: REFERENCE _____________________________

OFFER DATED _________________ . YOUR OFFER ON SOLICITATION (BLOCK

5) INCLUDING ANY ADDITIONS OR CHANGES WHICH ARE SET FORTH

HEREIN, IS ACCEPTED AS TO ITEMS:

30a. SIGNATURE OF OFFEROR/CONTRACTOR 31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER)

30b. NAME AND TITLE OF SIGNER (Type or print) 30c. DATE SIGNED 31b. NAME OF THE CONTRACTING OFFICER (Type or print)

Kathrine R. Leach

31c. DATE SIGNED

AUTHORIZED FOR LOCAL REPRODUCTION

PREVIOUS EDITION IS NOT USABLE

STANDARD FORM 1449 (REV. 11/2021)

Prescribed by GSA - FAR (48 CFR) 53.212

X

15DDHQ25Q00000093 Page 2 of 58

Section 1 - Commodity or Services Schedule

SCHEDULE OF SUPPLIES/SERVICES

CONTINUATION SHEET

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

Period of Performance: 08/01/2025-7/31/2026

U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non-Retail Settings IAW SOW Task 1 - Firm Fixed Price

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

0002 U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long-Term Care Facilities IAW SOW Task 1 - Firm Fixed Price

Line Period of Performance: 08/01/2025 - 07/31/2026

Firm Fixed Price

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

0003 U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2 - Firm Fixed Price

PSC: R702

Line Period of Performance: 08/01/2025 - 07/31/2026

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

4 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

0004 International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3 - Firm Fixed Price

PSC: R702

Line Period of Performance: 08/01/2025 - 07/31/2026

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

12 MO0001

15DDHQ25Q00000093 Page 3 of 58

0005 Ad-Hoc Reports IAW SOW Task 4.3

THIS WILL BE A Not To Exceed (NTE) CLIN AT

AWARD.

PSC: R702

Line Period of Performance: 08/01/2025 - 07/31/2026

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

0006 Additional Drugs - U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non- Retail Settings IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2025 - 07/31/2026

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

0007 Additional Drugs - U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long- Term Care Facilities IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2025 - 07/31/2026

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

0008 Additional Drugs - U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2

PSC: R702

Line Period of Performance: 08/01/2025 - 07/31/2026

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

0009 Additional Drugs - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3

PSC: R702

Line Period of Performance: 08/01/2025 - 07/31/2026

1 EA $________ $_________________

15DDHQ25Q00000093 Page 4 of 58

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

0010 Additional Countries - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task

PSC: R702

Line Period of Performance: 08/01/2025 - 07/31/2026

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

1001 U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non-Retail Settings IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

1002 U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long Term Care Facilities IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

1003 U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

4 EA $________ $_________________

15DDHQ25Q00000093 Page 5 of 58

Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

1004 International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

1005 Ad-Hoc Reports IAW SOW Task 4.3

THIS WILL BE A Not-To-Exceed(NTE) CLIN AT AWARD

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

1006 Additional Drugs - U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non- Retail Settings IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

1007 Additional Drugs - U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long- Term Care Facilities IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

15DDHQ25Q00000093 Page 6 of 58

1008 Additional Drugs - U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

1009 Additional Drugs - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

1010 Additional Countries - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task

PSC: R702

Line Period of Performance: 08/01/2026 - 07/31/2027

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2001 U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non-Retail Settings IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2027 - 07/31/2028

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2002 U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long-Term Care Facilities IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2027 - 07/31/2028

12 MO $________ $_________________

15DDHQ25Q00000093 Page 7 of 58

Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2003 U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2

PSC: R702

Line Period of Performance: 08/01/2027 - 07/31/2028

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

4 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2004 International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3

PSC: R702

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2005 Ad-Hoc Reports IAW SOW Task 4.3

THIS WILL BE A Not-To-Exceed (NTE) CLIN AT AWARD

PSC: R702

Line Period of Performance: 08/01/2027 - 07/31/2028

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2006 Additional Drugs - U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non- Retail Settings IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2027 - 07/31/2028

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive

15DDHQ25Q00000093 Page 8 of 58

Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2007 Additional Drugs - U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long- Term Care Facilities IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2027 - 07/31/2028

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2008 Additional Drugs - U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2

PSC: R702

Line Period of Performance: 08/01/2027 - 07/31/2028

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2009 Additional Drugs - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3

PSC: R702

Line Period of Performance: 08/01/2027 - 07/31/2028

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

2010 Additional Countries - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task

PSC: R702

Line Period of Performance: 08/01/2027 - 07/31/2028

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

15DDHQ25Q00000093 Page 9 of 58

3001 U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non-Retail Settings IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

3002 U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long-Term Care Facilities IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

3003 U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

4 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

3004 International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

3005 Ad-Hoc Reports IAW SOW Task 4.3

THIS WILL BE A Not-To-Exceed(NTE) CLIN AT AWARD

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

15DDHQ25Q00000093 Page 10 of 58

Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

3006 Additional Drugs - U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non- Retail Settings IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

3007 Additional Drugs - U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long- Term Care Facilities IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

3008 Additional Drugs - U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

3009 Additional Drugs - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

15DDHQ25Q00000093 Page 11 of 58

Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

3010 Additional Countries - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task

PSC: R702

Line Period of Performance: 08/01/2028 - 07/31/2029

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

4001 U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non-Retail Settings IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

4002 U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long-Term Care Facilities IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

4003 U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

4 EA $________ $_________________

15DDHQ25Q00000093 Page 12 of 58

4004 International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

12 MO $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

4005 Ad-Hoc Reports IAW SOW Task 4.3

THIS WILL BE A Not-To-Exceed(NTE) AT AWARD

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

4006 Additional Drugs - U.S. Monthly Pharmaceutical Purchase Data Drug Store Retailers and Non- Retail Settings IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

4007 Additional Drugs - U.S. Monthly Pharmaceutical Prescription Data Independent and Chain Retail Pharmacies, Mail Order and Long- Term Care Facilities IAW SOW Task 1

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

4008 Additional Drugs - U.S. Quarterly Pharmaceutical Data by State IAW SOW Task 2

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

15DDHQ25Q00000093 Page 13 of 58

Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

4009 Additional Drugs - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task 3

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

1 EA $________ $_________________

ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

4010 Additional Countries - International Countries Monthly Pharmaceutical Purchase and Prescription Data IAW SOW Task

PSC: R702

Line Period of Performance: 08/01/2029 - 07/31/2030

Delivery Schedule:

Quantity: 1.000000

Delivery Address: DEA Attn: Diversion Control Division(DC) 8701 Morrissette Drive Springfield, VA 22152-1080

STATEMENT OF WORK

Pharmaceutical Prescription Data

Table of Contents 1 Introduction

2 Background/Objective

3 Requirements

3.1 General Requirements

3.2 General Drug Data Requirements

4 Tasks

4.1 Domestic Drug Data

4.1.1 Prescription Audit Data

4.2 International Drug Data

4.3 Ad-Hoc Reporting

4.4 Task Deliverables

5 General Support and Training

6 Administration

6.1 Period of Performance

6.2 Security

6.3 Contract Officer’s Representative (COR)

6.5 Invoicing

7 Appendices

Appendix A: Domestic List of Substances

Appendix B: International List of Substances

Appendix C: List of Countries

Appendix D: Drug Data Elements

1 Introduction The mission of the Drug Enforcement Administration (DEA) is to enforce the controlled substances laws and regulations of the United States (U.S.) and bring to the criminal and civil justice system of the U.S., or any other competent jurisdiction, those organizations and principal members of organizations, involved in the growing, manufacture, or distribution of controlled substances appearing in or destined for illicit traffic in the U.S.; and to recommend and support non-enforcement programs aimed at reducing the availability of illicit controlled substances on the domestic and international markets.

Of all the major drugs of abuse, only marijuana is available as a natural, harvested product. The others, whether they are illicit drugs such as cocaine, heroin, methamphetamine, or legitimately produced pharmaceuticals, must be manufactured. Many problems associated with drug abuse are the result of legitimately made controlled substances being diverted from their lawful purpose into illicit drug traffic.

The mission of DEA's Diversion Control Division is to prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs.

DEA’s Diversion Control Division oversees the Diversion Control Program and carries out the mandates of the Controlled Substances Act by preventing the diversion of controlled substances and listed chemicals into the illicit market while ensuring a sufficient supply of the substances and chemicals for legitimate medical, scientific, research, and industrial purposes. Major components of the Diversion Control Program include:

1. Scheduling controlled substances,

2. Setting production quotas for certain controlled substances and regulated chemicals,

3. Establishing import and export controls,

4. Investigating DEA registrants to detect diversion and, where diversion occurs, prosecuting violators,

5. Conducting liaison with industries and associations representing registrants,

6. Assisting state and local authorities, and

7. Maintaining international liaison and representing the U.S. on matters related to controlled substances and regulated chemicals at the United Nations.

The Diversion Control Division directs the worldwide DEA Diversion Control Program to include domestic and international diversion control, registration, voluntary compliance, state and local assistance, industry liaison, and associated support programs. The Diversion Control Division maintains an overall geographic picture of drug and chemical diversion and abuse problems to identify new trends or patterns in diversion and abuse. This enables the Diversion Control Division to appropriately direct resources. The Diversion Control Program is executed by maintaining the closed system of distribution, regulating and controlling over 1.5 million DEA registrants, and investigating activity related to the diversion of controlled substances and listed chemicals.

2 Background/Objective The Drug Enforcement Administration (DEA) is required by 21 U.S.C. 826 to establish the amounts of certain drugs that are to be produced in the U.S. each year and to equitably apportion those amounts among the producers. The objective of this contract is to obtain data to determine the amounts of certain drugs that should be allowed for production, annually.

Many of the narcotics, depressants, and stimulants manufactured for legitimate medical use are subject to abuse and have, therefore, been brought under legal control. Under federal law, all businesses that import, export, manufacture, or distribute controlled substances; all health professionals licensed to dispense, administer, or prescribe them; and all pharmacies authorized to bill prescriptions must register with the DEA. DEA registrants must comply with regulatory requirements relating to drug security and recordkeeping. The DEA is also obligated under international treaties to monitor the movement of licit controlled substances across U.S. borders and to issue import and export permits for that movement.

Fees paid by DEA registrants, such as manufacturers, distributors, dispensers (including physicians), importers, and exporters of controlled substances (such as narcotics and stimulants) and certain listed chemicals (such as ephedrine) are deposited in the Diversion Control Fee Account. Fees collected are used to recover the full costs of the program, including personnel costs and operation costs such as investigative costs, travel, and the purchase of goods and services.

3 Requirements

3.1 General Requirements

The contractor shall:

1. Furnish the necessary personnel, materials, services, facilities, and other items necessary for or incidental to, the provision of the work described in this work statement.

2. Provide online, 24 hours a day, 7 days a week pharmaceutical data access to DEA in a database format, which allows DEA to search and query the database and produce output reports, for the duration of this contract.

a. Additionally, the data provided should be collated on a monthly, quarterly, annual and year-to-date basis.

3. Collect the required data, provide access to the required data and establish and maintains the databases

4. Provide a solution that is equal to, or better than the following brand name IQVIA products:

a. National Prescription Audit ®,

b. National Sales Perspective ®, and

c. MIDAS ®, Equal solutions shall provide coverage that is comprehensive for the national U.S. data, to include at least 94% of all dispensed prescription drug data and at least 90% of all pharmaceutical sales data. Projections to the national and country levels shall employ methodologies proven to be accurate and reliable.

5. Provide the capability of exporting data to a spreadsheet application (Microsoft Excel) for data manipulation and production of charts/graphs.

6. Provide timely updates (including national projections) each calendar month, within eight (8) weeks of the end of the calendar month.

a. For example, the contractor shall provide January 2025 data no later than eight (8) weeks after January 31, 2025 (e.g. received by DEA prior to April 2025).

7. The solution shall provide DEA with U.S. State drug data for two (2) years on a rolling history basis for trending purposes.

8. The solution shall provide DEA with National level data dating back to 1992 for all drugs from Appendix A: Domestic Drug List, for trending purposes.

9. Provide the DEA with data for international countries, groups of countries, and U.S. territories for six (6) years, on a rolling history basis, for all drugs from Appendix B: International Drug List, for trending purposes.

3.2 General Drug Data Requirements

DEA will use the data products provided via this contract, in performance of its mission and/or accomplishing its goals. DEA may share information generated from the data products with other Government Agencies, organizations, and/or the general public with prior clearance by the contractor. The contractor shall:

1. Provide purchase and prescription dispensing data that differentiates between manufacturers and dosage strengths, is sorted and able to be queried, and includes the attributes listed in Appendix D: Drug Data Elements.

Description of required Data and Reports

1. Long Term Care Data: measures the dispensing of non-retail prescriptions by nursing homes with in-house pharmacies and by nursing home provider contract pharmacies within the U.S.

projected to national levels.

2. Mail Order Prescription Data: Measures the outflow of prescriptions via formal prescriptions from mail order pharmacies in the U.S. projected to national levels.

3. National/Country Prescription Data: Measure of the retail outflow of prescriptions, or the rate at which drugs move out of independent and chain retail pharmacies into the hands of the consumers via formal prescriptions, in the U.S. and international countries, groups of countries, and/or U.S. territories projected to national/country levels.

4. Consolidated Prescription Data Report: Report to include a total of (1) Long Term Care Data;

(2) Mail Order Prescription Data; and (3) National Prescription Data into a Total U.S.

Prescription Projection.

5. Drugstores/Pharmacy Purchase Data: Data on the purchases made by retailers of prescription and OTC drugs and drug products projected to national/country levels.

6. Non-Retail Purchase Data: Data on the purchases made by hospitals and other non- retail settings (specified above) of prescription and OTC drugs and drug products projected to national/country levels.

7. Consolidated Purchase Data Report: Report to include a total of Drugstores/Pharmacy Purchase Data and Non-Retail Purchase Data into a Total U.S. Drug Purchase Projection.

8. State and MSA Report: Report to include prescription audit regional data by State and MSA for the retail, long term care and mail order channels, on a quarterly basis.

4 Tasks

4.1 Domestic Drug Data

The Contractor shall provide data as described below in accordance with the details herein:

1. Purchases by drug store retailers (i.e. independent pharmacies, chain pharmacies/mass merchandisers, food stores with pharmacies, and mail order pharmacies) of specific prescription and over-the-counter (OTC) drugs and drug products projected to national U.S. levels.

2. Purchases by non-retail settings (including U.S. Non-Federal hospitals, HMO’s, Clinics, Universities, Long term care facilities, Home Health Care, Federal Facilities and Prisons) of prescription and OTC drugs and drug products projected to national U.S. levels.

3. A measure of the retail outflow of prescriptions from independent and chain retail pharmacies via formal prescriptions projected to national U.S. levels.

4. A measure of the outflow of prescriptions via formal prescriptions from mail order pharmacies and long-term care facilities projected to national U.S. levels.

5. All data shall be accessible via a PC-based software or online application that enables the automated retrieval and manipulation of data.

This information shall be provided monthly, based on the information in Appendix A: Domestic List of Substances. DEA has the option of redesignating which drugs are included monthly, through communication between the COR and contractor on an ongoing basis, for the duration of this contract.

4.1.1 Prescription Audit Data

1. Prescription audit regional data for the U.S. by State and MSA for the retail, long term care and mail order channels, on a quarterly basis.

2. All data shall be accessible via a PC-based software or online application that enables the automated retrieval and manipulation of data.

4.2 International Drug Data

The contractor shall provide drug data monthly for international countries, groups of countries, and/or U.S. territories from Appendix C: List of Countries, as described below in accordance with the details herein:

1. Purchases by drug store retailers (i.e. retail pharmacies) of specific prescription and over-the-counter (OTC) drugs and drug products projected to country levels.

2. Purchases by non-retail settings (including hospital pharmacies) of prescription and OTC drugs and drug products projected to country levels.

3. A measure of the retail outflow of prescriptions from drug store retailers (i.e. retail pharmacies) via formal prescriptions projected to country levels.

4. A measure of the outflow of prescriptions via formal prescriptions from non-retail settings (including hospital pharmacies) projected to country levels.

5. All data shall be accessible via a PC-based software or online application that enables the automated retrieval and manipulation of data.

This information shall be provided monthly, based on the information in Appendix B: International List of Substances. DEA has the option of redesignating which drugs and/or international countries, groups of countries, and/or U.S. territories are included, through communication between the COR and contractor on an ongoing basis, for the duration of this contract.

4.3 Ad-Hoc Reporting

The Contractor shall provide, as required special Ad-Hoc reports for various types of audit data contained in its database, upon request from the COR/CO. The Ad-Hoc reports will be coordinated between the COR and Contractor prior to a request being issued from the Contracting Officer in order to ensure the data is available and meets the Governments requirements. Upon receipt of the request, the contractor shall promptly provide DEA with a price quotation for providing the requested ad-hoc report(s) based on the Governments need. Following agreement by the parties on all aspects of the request, DEA will issue an appropriate modification to the contract providing funding for the report. The corresponding CLINS on the contract for these reports are Not To Exceed (NTE) in value and should not be exceeded without a written modification from a Contracting Officer.

4.4 Task Deliverables

Reference Deliverable Schedule

3.1 (2) 24/7 Access to data/database Duration of Period of Performance or agreed upon following award

4.1 Drug Data Projected to National Levels Monthly (within 8 weeks of end of calendar month)

4.1.1 State-level and MSA data for retail, long term care and mail order channels

Quarterly (within 8 weeks of end of calendar quarter)

4.2 Drug Data Projected to Country Levels Monthly (within 8 weeks of end of calendar month)

4.3 Ad Hoc Data/Reports As needed and agreed upon between contractor and DEA

5 General Support and Training The contractor will provide training to DEA on query capabilities and use of the furnished solution.

Access shall be provided for up to fifty (50) DEA employees, to have capability of accessing the online system simultaneously.

The Contractor shall provide technical assistance and support to DEA, as needed for all the following items (as applicable): installation, operation and updating the solution. This support shall be provided as part of the furnished solution, at no additional cost to the government.

6 Administration

6.1 Period of Performance

The Government intends to issue an award for these services, for an initial twelve (12) month base period, followed by optional periods, not to exceed sixty (60) months of performance.

Period of performance:

Base Period: 8/1/2025 – 7/31/2026 Option Period 1: 8/1/2026 – 7/31/2027 Option Period 2: 8/1/2027 – 7/31/2028 Option Period 3: 8/1/2028 - 7/31/2029 Option Period 4: 8/1/2029 – 7/31/2030

The Government will include FAR 52.217-8 Option to Extend the Term of the Contract – for a period not to exceed 6 months of additional services. This option is exercisable at the prices established in Option Period 4 of the contract.

6.2 Security

All contractor personnel supporting this procurement are entrusted with a certain level of trust due to the nature of DEA's mission. The Government expects the vendor will employ persons of integrity and trustworthiness. To ensure this, DEA reserves the right to conduct background screening or a full background investigation on all employees if a need arises. While all services provided on this contract will be performed outside of DEA, all contractors must be escorted if entering a DEA facility. DEA reserves the right to modify the security requirements found in this contract at any time. In addition, all contract personnel supporting this project shall complete and submit a security Standard Form 85 before entering the compound to start work.

6.3 Contract Officer’s Representative (COR)

To be Determined at time of award.

6.4 Place of Performance

All work performed under this contract will be at the contractor’s facility.

6.5 Invoicing

Submission of an accurate invoice that includes all the requirements listed below, will ensure timely payment. Invoices will be carefully inspected by the COR. Invoices that are incorrect or which are lacking information will be rejected. A proper invoice is defined in FAR 32.905 and must contain the minimum information for processing:

Name and address of the contractor Invoice date and invoice number Contract number or other authorization for supplies delivered or services performed (including order number and line item number) Description, quantity, unit of measure, unit price, and extended price of supplies delivered or services performed Shipping and payment terms Name and address of contractor official to whom payment is to be sent Name (where practicable), title, phone number, and mailing address of person to notify in the event of a defective invoice Taxpayer Identification Number (TIN)

7 Appendices

Appendix A: Domestic List of Substances 4-Hydroxybutyric Acid Alfentanil Alprazolam Atomoxetine Amobarbital Amphetamine Belladona Benzphetamine Benzhydrocodone Boldione Brexanolone Buprenorphine Bupropion Butabarbital Butalbital Butorphanol Carbinoxamine Carisoprodol Cenobamate Chloral Hydrate Chlordiazepoxide Clonazepam Clorazepate Cocaine Codeine Cyclobenzaprine Desoxymethyltestosterone Dexfenfluramine Dexmethylphenidate Dexmedetomidine Dextroamphetamine Dextromethorphan Dextropropoxyphene Diazepam Dichloralphenazone Diethylpropion Difenoxin Dihydrocodeine Diphenhydramine Diphenoxylate Dronabinol Ebutramide Eluxadoline Ephedrine

Esketamine Estazolam Eszopiclone Ethchlorvynol Ethinamate Fenfluramine Fentanyl Fluoxetine Fluoxymesterone Flurazepam Fospropofol Gabapentin Halazepam Hydrocodone Hydromorphone Indiplon Ketamine Lacosamide Lasmiditan Lemborexant Levorphanol Lisdexamfetamine Lorazepam Lorcaserin Meperidine Meprobamate Methadone Methamphetamine Methohexital Methylphenidate Methylphenobarbital Methyltestosterone Methylprylon Midazolam Modafinil Morphine Nabilone Nalbuphine Nalmefene Naloxone Naltrexone Nandrolone Oliceridine Opium

Oripavine Oxandrolone Oxazepam Oxycodone Oxymetholone Oxymorphone Paraldehyde Pemoline Pentazocine Pentobarbital Perampanel Phendimetrazine Phenobarbital Phentermine Phenylephrine Phenylpropanolamine Prazepam Pregabalin Propofol Propoxyphene Pseudoephedrine Quazepam Remifentanil Retigabine Secobarbital Serdexmethylphenidate Sibutramine Sodium Oxybate (GHB) Solriamfetol Stanozolol Sufentanil Suvorexant Talbutal Tapentadol Temazepam Testosterone Thiopental Tramadol Triazolam Zaleplon Zolpidem Zopiclone

Appendix B: International List of Substances Alfentanil Amobarbital Amphetamine Benzhydrocodone Cocaine Codeine Dexmethylphenidate Dextroamphetamine Dextropropoxyphene Dihydrocodeine Diphenoxylate

Dronabinol Fentanyl Hydrocodone Hydromorphone Levorphanol Lisdexamfetamine Meperidine Methadone Methamphetamine Methylphenidate Morphine

Nabilone Oliceridine Opium Oripavine Oxycodone Oxymorphone Pentobarbital Remifentanil Secobarbital Sufentanil Tapentadol

Appendix C: List of Countries Algeria Argentina Australia Austria Belarus Belgium Bolivia Bosnia Brazil Bulgaria Canada Central America Chile China Colombia Croatia Czech Republic Dominican Republic Ecuador Egypt Estonia Finland France

Germany Greece Hungary India Ireland Italy Japan Jordan Kazakhstan Korea Kuwait Latvia Lebanon Lithuania Luxembourg Mexico Morocco Netherlands New Zealand Norway Pakistan Peru Philippines

Poland Portugal Puerto Rico Romania Russia Saudi Arabia Serbia Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Thailand Tunisia Turkey United Arab Emirates United Kingdom Uruguay Venezuela West Africa

Appendix D: Drug Data Elements Average Daily Consumption Average Days of Therapy per Prescription Branded product vs. generic product

By manufacturer and corporation By pack size By product and form (e.g. solids, liquids) By route of administration and product form (e.g. systemic vs. topical product, injectable vs. oral vs.

sublingual vs. implant) By strength (e.g. mg of active ingredient) Calendar Year Channel/source of drug (differentiation between type of distribution channel e.g. pharmacy vs. grocery store vs. convenience store, etc.)

Data Collated by Time Period Categories Data Measures Dispensed Refill Prescriptions Dispensed Total Prescriptions Extended Dosage Units Purchased Kilograms Purchased Month Non-Retail Purchase Data Number of Dispensed New Prescriptions Number of Dispensed Refill Prescriptions Prescription Data (including Pharmacies, Mail Order Facilities and Long Term Care Facilities) Prescription Data by State Retail Pharmacy Purchase Data Single entity drug product vs. multi-active ingredient product Sustained release vs. immediate release formulations Time Periods Total Number Dispensed Prescriptions (New and Refill) Total Number of Dosage Units of Drug contained within Total Prescriptions Traditional Quarter Use of Data Year-To-Date

INSTRUCTIONS, CONDITIONS AND NOTICE TO OFFERORS

1. COMMITMENT OF GOVERNMENT TO AWARD A SINGLE AWARD CONTRACT:

As a result of the solicitation, the Government intends to make a single Firm Fixed Price award with a total ordering period of 60 months, with an additional option for a 6-month extension IAW FAR 52.217-8 at the Governments discretion. This solicitation does not commit the Government to award a contract.

2. COMMUNICTIONS

All communications concerning the solicitation, including any of a technical nature, shall be submitted via email to Kathrine.r.leach@dea.gov. All questions, technical or otherwise, in response to this solicitation shall be in writing and receive by the government on or before 11 June 2025 by 1:00PM Eastern Time. Questions shall identify the applicable section, page number and paragraph in which it relates to. The Government will provide responses to all Quoters in the form of an amendment to the solicitation. The Government reserves the right to award without communications to include discussions or clarifications.

3. QUOTE PREPARATION AND SUBMISSION INSTRUCTIONS IAW FAR 52.212-1-

Instructions to offerors –commercial items:

3.1 TIME, DATE, and PLACE: Offerors shall submit their signed, complete and final quote including all Factors and any additional information as required in this solicitation in a Microsoft compatible format no later than 4:00 PM Eastern Time on 16 June 2025. Late submissions will not be considered for award. Quotes shall be emailed to Kathrine.r.leach@dea.gov.

3.2 QUOTE PREPARATIONS AND SUBMISSION - GENERAL:

1. The Offeror’s quote shall be clearly marked with the Request for Quote number "15DDHQ25Q00000093 - RX Pharmaceutical Prescription Data".

2. The Offeror’s quote shall provide any and all assumptions associated with the Offeror’s submission in response to the Government’s solicited requirement and shall confirm conformance to all clauses and provisions as established in this solicitation.

3. The Offeror agrees to hold the prices in its quote firm for 90 calendar days from the date specified for receipt of offers, unless another time period is specified in an addendum to the solicitation.

4. The Offeror’s quote shall be submitted in an electronic format and shall be clear and concise, neat, indexed, and logically assembled.

mailto:Kathrine.r.leach@dea.gov

5. The Offeror’s quote shall be prepared and submitted in two separate volumes and clearly labeled:

a. Volume I – Technical Quote*(2 versions see note below)

b. Volume II – Price Quote (only 1 version)

6. The quote shall be prepared and submitted in two (2) separate volumes clearly labeled as Volume I “Technical Quote” and Volume II: “Price Quote.” Each volume shall be separate and complete so that evaluation of one volume may be accomplish independently of evaluating the other.

7. *Technical Quote – One (1) technical quote shall be submitted with all company information, names, logos etc in a viewable and clear format and one (1) separate copy shall be submitted with all company logos, names, and any identifying information of the firm redacted.

8. Price Quote – the price quote shall be completed using the schedule of services in the RFQ. Offerors may propose in a separate Microsoft Excel document – but the format of the schedule provided shall be used to include the base and all option periods.

9. The Government reserves the right to award without communications and therefore if the Offeror fails to include the necessary information in the appropriate quote volume, it will not be considered.

10. Quotes shall be prepared in accordance with these instructions. Failure to do so may result in the Offeror’s submission being determined unacceptable and ineligible for award. Each Offeror’s submission shall be screened by the CO upon receipt to ensure completeness and compliance with the instructions contained in the Request for Quote (RFQ).

Elimination of an Offeror is at the sole discretion of the CO.

11. Each Offeror shall submit a quote that clearly and concisely describes its response to the requirements of the solicitation. Use of general or vague statements such as “standard procedures will be used” will not satisfy this requirement. Unnecessary elaboration or presentations beyond what is sufficient to present a complete and effective solution are not desired and may be construed as a lack of understanding of the requirement.

3.3 VOLUME 1 – TECHNICAL QUOTE INSTRUCTIONS: Offeror shall submit a technical quote to be considered for award. The Offeror’s technical quote shall not exceed 7 typed, double sided (14 single sided) pages with one-inch margins, Times New Roman font, and 12 pitch type.

Any pages in excess of the page limitation will be removed, disregarded, and not evaluated. The Offeror’s technical quote shall address the following:

Factor 1: Technical Capability – Volume 1:

The offeror shall clearly demonstrate their solution as the brand name requested in the RFQ or clearly demonstrate their solution as an “or equal” meets all SOW requirements and IAW FAR 52.211-6. Offerors providing “equal” products/ solutions to the SOW requirements are responsible for clearly providing detailed information to include but not limited to descriptive literature, drawings or references to demonstrate their product/solution provides the required support.

In addition to the SOW, offerors shall demonstrate how their product/solution provides the following:

(1) Breadth of market for which actual data collected for (i.e. percentage of total independent pharmacies, chain pharmacies/mass merchandisers, food stores with pharmacies, mail service pharmacies, U.S. Non-Federal hospitals, HMO’s, Clinics, Universities, Long term care facilities, Home Health Care, Federal Facilities and Prisons for which purchase data is collected), and percentage of total U.S. prescriptions collected for independent and chain retail pharmacies, mail order pharmacies and long term care facilities as part of data sample.

(2) Time frame data in which data collated (by calendar month, quarter, calendar year, year to date etc.)

(3) Timeliness of collection of data and dissemination of data to client.

(4) Level of detail of data, including details pertaining to package size, dosage form (i.e. liquid, solid ,soft gel, suspension), number dosage units, kilogram of drug distributed/dispensed, average days dosing per prescription, average size prescription.

(5) Ability to project data for pharmaceutical purchases and prescriptions to national levels.

(6) Demonstration that data collected for drugs of interest.

(7) Ability to provide data in a format which allows client to electronically search and query data and produce output reports via automated software and export to spreadsheet packages in Microsoft-Excel.

The Government will not request additional information to make an equivalent determination. The Government will not use any previous knowledge in determining a product/solution as equal and will solely base its evaluation on the documentation provided in the quote.

Subfactor 1: Past Performance – Volume 1:

The Government will review offerors past performance on similar contracts, including customer satisfaction, adherence to schedules and quality of work.